Navigation Links
Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
Date:8/25/2009

QUEBEC CITY, Aug. 25 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase I human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrollment of volunteers is now underway.

The Phase I placebo-controlled, double-blind, dose-escalating study will evaluate safety, tolerability and the immune response of the Company's H5N1 vaccine candidate in up to 48 healthy volunteers between the ages 18 to 60. Volunteers will receive two doses, injected 21 days apart of either a placebo or the influenza vaccine at doses of 5, 10 or 20 micrograms. The trial will take place at the Vaccine Evaluation Center of McGill University in Montreal, Canada, under the supervision of Dr. Brian Ward. Results of this study are expected during the fourth quarter of 2009.

"The acceptance of our Clinical Trial Application by Health Canada represents a major milestone in the company's development of novel influenza vaccines. It is a testament to the quality of our technology and demonstrates our ability to advance candidates towards human trials," said Andy Sheldon, President and CEO of Medicago. "This trial will be the first in which a plant-based vaccine will be injected into humans in Canada. We believe we have a compelling vaccine against influenza - a candidate, which at low dosage may protect against different strains of influenza that have the potential of becoming a pandemic. Combined with our rapid response and low cost manufacturing capabilities, we believe our vaccine can address an unmet gap in pandemic influenza preparedness efforts."

"All of our studies to date confirm that we have a safe and effective vaccine candidate entering human trials," said Nathalie Landry, VP Product
'/>"/>

SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Medicago initiates work on Swine Flu strain
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership
6. Foamix Receives US Patent on Novel Foam Technology
7. SyntheMed Receives Russian Regulatory Approval for REPEL-CV(TM)
8. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
9. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
10. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
11. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Women in the ... to an additional family planning option. Sayana® Press ... at all levels of the health system and ... a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with ... is the first of four African countries expected ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been ... comes with a second treatment cup to help prevent and ... cup is thinner on the edges for a softer contact ... and uneven surfaces on the face, neck and décolleté. Choose ... on areas such as the cheeks and neck, or opt ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2
... Jan. 20, 2011 MedImmune,s Oncology group announced today ... broadly suppresses pathways that have been shown to play ... many solid tumors. The study, published in the February ... of the American Association for Cancer Research), suggests that ...
... Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, ... company that creates, develops and tests innovative HIV/AIDS vaccines, is ... Community Awards.  Dr. Robinson will be honored at the GaBio ... Atlanta,s Fox Theater. Dr. Robinson is the developer ...
... 2011 Reportlinker.com announces that a new market ... Hospital General Radiology Census ... is the most comprehensive European market report on ... IT systems (PACS) in European hospitals. Hospitals are ...
Cached Biology Technology:Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells 2Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells 3GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony 2GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony 3Reportlinker Adds Hospital General Radiology Census 2
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... software and services, previously announced on June 26, 2014 ... cash dividend of $1.75 per share, or approximately $40 ... of July 10, 2014 and a payment date of ... NASDAQ that it had set an ex-dividend date for ...
(Date:7/10/2014)... 2014 According to the new ... And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), ... Banking & Finance), and Geography - Global Trends & ... global Fingerprint Sensors Market is projected to cross $14.35 ... 16.8% from 2014 to 2020. Browse more ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... St. Jude Children,s Research Hospital have reported details of ... enzyme essential for the influenza virus, replication. Since all ... researchers believe their findings will yield drugs that can ... be resistant to current antiviral treatments. When new ...
... State University suggest that a "fight" between bacteria normally living ... another type of bacteria, may be linked to two types ... continues after the instigator bacteria have been cleared by the ... GSU Center for Inflammation, Immunity and Infection. That fight can ...
... UCLA stem cell researchers have found for the first ... endothelium, the place where blood stem cells are made ... lack of one transcription factor, a type of gene ... the precursors that normally generate blood stem and progenitor ...
Cached Biology News:Target for potent first-strike influenza drugs identified 2Target for potent first-strike influenza drugs identified 3Target for potent first-strike influenza drugs identified 4Embryonic blood vessels that make blood stem cells can also make beating heart muscles 2Embryonic blood vessels that make blood stem cells can also make beating heart muscles 3
Hamster serum...
... Cy5 Post-Labeling Reactive Dye Pack, ... CyDye fluors specifically optimized for microarray ... 40000 pmol reactive dye per vial, ... to use, individually dispensed, and packed ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
Biology Products: